230 related articles for article (PubMed ID: 36787937)
1. Effects of Intensive Systolic Blood Pressure Lowering on End-Stage Kidney Disease and Kidney Function Decline in Adults With Type 2 Diabetes Mellitus and Cardiovascular Risk Factors: A Post Hoc Analysis of ACCORD-BP and SPRINT.
Tawfik YMK; Van Tassell BW; Dixon DL; Baker WL; Fanikos J; Buckley LF
Diabetes Care; 2023 Apr; 46(4):868-873. PubMed ID: 36787937
[TBL] [Abstract][Full Text] [Related]
2. Effects of Intensive Systolic Blood Pressure Lowering on Cardiovascular Events and Mortality in Patients With Type 2 Diabetes Mellitus on Standard Glycemic Control and in Those Without Diabetes Mellitus: Reconciling Results From ACCORD BP and SPRINT.
Beddhu S; Chertow GM; Greene T; Whelton PK; Ambrosius WT; Cheung AK; Cutler J; Fine L; Boucher R; Wei G; Zhang C; Kramer H; Bress AP; Kimmel PL; Oparil S; Lewis CE; Rahman M; Cushman WC
J Am Heart Assoc; 2018 Sep; 7(18):e009326. PubMed ID: 30371182
[TBL] [Abstract][Full Text] [Related]
3. Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP.
Buckley LF; Dixon DL; Wohlford GF; Wijesinghe DS; Baker WL; Van Tassell BW
Diabetes Care; 2017 Dec; 40(12):1733-1738. PubMed ID: 28947569
[TBL] [Abstract][Full Text] [Related]
4. Intensive Blood Pressure Lowering in Patients With and Patients Without Type 2 Diabetes: A Pooled Analysis From Two Randomized Trials.
Brouwer TF; Vehmeijer JT; Kalkman DN; Berger WR; van den Born BH; Peters RJ; Knops RE
Diabetes Care; 2018 Jun; 41(6):1142-1148. PubMed ID: 29212825
[TBL] [Abstract][Full Text] [Related]
5. Initial Estimated Glomerular Filtration Rate Decline and Long-Term Renal Function During Intensive Antihypertensive Therapy: A Post Hoc Analysis of the SPRINT and ACCORD-BP Randomized Controlled Trials.
Collard D; Brouwer TF; Olde Engberink RHG; Zwinderman AH; Vogt L; van den Born BH
Hypertension; 2020 May; 75(5):1205-1212. PubMed ID: 32223381
[TBL] [Abstract][Full Text] [Related]
6. Influence of Prediabetes on the Effects of Intensive Systolic Blood Pressure Control on Kidney Events.
Rathi N; Whelton PK; Chertow GM; Cushman WC; Cheung AK; Wei G; Boucher R; Kimmel PL; Bress AP; Kramer HJ; Al-Marji C; Greene T; Beddhu S
Am J Hypertens; 2019 Nov; 32(12):1170-1177. PubMed ID: 31257407
[TBL] [Abstract][Full Text] [Related]
7. Effects of Intensive Blood Pressure Control in Patients with and without Albuminuria:
Chang AR; Kramer H; Wei G; Boucher R; Grams ME; Berlowitz D; Bhatt U; Cohen DL; Drawz P; Punzi H; Freedman BI; Haley W; Hawfield A; Horwitz E; McLouth C; Morisky D; Papademetriou V; Rocco MV; Wall B; Weiner DE; Zias A; Beddhu S;
Clin J Am Soc Nephrol; 2020 Aug; 15(8):1121-1128. PubMed ID: 32669306
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes.
Mottl AK; Buse JB; Ismail-Beigi F; Sigal RJ; Pedley CF; Papademetriou V; Simmons DL; Katz L; Mychaleckyj JC; Craven TE
Clin J Am Soc Nephrol; 2018 Nov; 13(11):1693-1702. PubMed ID: 30361335
[TBL] [Abstract][Full Text] [Related]
9. The Influence of Baseline Diastolic Blood Pressure on the Effects of Intensive Blood Pressure Lowering on Cardiovascular Outcomes and All-Cause Mortality in Type 2 Diabetes.
Ilkun OL; Greene T; Cheung AK; Whelton PK; Wei G; Boucher RE; Ambrosius W; Chertow GM; Beddhu S
Diabetes Care; 2020 Aug; 43(8):1878-1884. PubMed ID: 32366577
[TBL] [Abstract][Full Text] [Related]
10. Benefit and harm of intensive blood pressure treatment: Derivation and validation of risk models using data from the SPRINT and ACCORD trials.
Basu S; Sussman JB; Rigdon J; Steimle L; Denton BT; Hayward RA
PLoS Med; 2017 Oct; 14(10):e1002410. PubMed ID: 29040268
[TBL] [Abstract][Full Text] [Related]
11. Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Hypertension: SPRINT (Systolic Blood Pressure Intervention Trial).
Soliman EZ; Ambrosius WT; Cushman WC; Zhang ZM; Bates JT; Neyra JA; Carson TY; Tamariz L; Ghazi L; Cho ME; Shapiro BP; He J; Fine LJ; Lewis CE;
Circulation; 2017 Aug; 136(5):440-450. PubMed ID: 28512184
[TBL] [Abstract][Full Text] [Related]
12. Potential Deaths Averted and Serious Adverse Events Incurred From Adoption of the SPRINT (Systolic Blood Pressure Intervention Trial) Intensive Blood Pressure Regimen in the United States: Projections From NHANES (National Health and Nutrition Examination Survey).
Bress AP; Kramer H; Khatib R; Beddhu S; Cheung AK; Hess R; Bansal VK; Cao G; Yee J; Moran AE; Durazo-Arvizu R; Muntner P; Cooper RS
Circulation; 2017 Apr; 135(17):1617-1628. PubMed ID: 28193605
[TBL] [Abstract][Full Text] [Related]
13. Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: secondary analyses of two randomised controlled trials.
Beddhu S; Greene T; Boucher R; Cushman WC; Wei G; Stoddard G; Ix JH; Chonchol M; Kramer H; Cheung AK; Kimmel PL; Whelton PK; Chertow GM
Lancet Diabetes Endocrinol; 2018 Jul; 6(7):555-563. PubMed ID: 29685860
[TBL] [Abstract][Full Text] [Related]
14. Individualising intensive systolic blood pressure reduction in hypertension using computational trial phenomaps and machine learning: a post-hoc analysis of randomised clinical trials.
Oikonomou EK; Spatz ES; Suchard MA; Khera R
Lancet Digit Health; 2022 Nov; 4(11):e796-e805. PubMed ID: 36307193
[TBL] [Abstract][Full Text] [Related]
15. Effects of Intensive Blood Pressure Treatment on Acute Kidney Injury Events in the Systolic Blood Pressure Intervention Trial (SPRINT).
Rocco MV; Sink KM; Lovato LC; Wolfgram DF; Wiegmann TB; Wall BM; Umanath K; Rahbari-Oskoui F; Porter AC; Pisoni R; Lewis CE; Lewis JB; Lash JP; Katz LA; Hawfield AT; Haley WE; Freedman BI; Dwyer JP; Drawz PE; Dobre M; Cheung AK; Campbell RC; Bhatt U; Beddhu S; Kimmel PL; Reboussin DM; Chertow GM;
Am J Kidney Dis; 2018 Mar; 71(3):352-361. PubMed ID: 29162340
[TBL] [Abstract][Full Text] [Related]
16. Effects of intensive blood pressure lowering in patients with diabetes: A pooled analysis of the STEP and ACCORD-BP randomized trials.
Yang R; Bai J; Fang Z; Wang Y; Feng Y; Liu Y; Chi H; Deng Y; Song Q; Cai J
Diabetes Obes Metab; 2023 Mar; 25(3):796-804. PubMed ID: 36433919
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of blood pressure-lowering treatment by the levels of baseline Framingham risk score: A post hoc analysis of the Systolic Blood Pressure Intervention Trial (SPRINT).
Zhang L; Sun X; Liao L; Zhang S; Zhou H; Zhong X; Zhuang X; Liao X
J Clin Hypertens (Greenwich); 2019 Dec; 21(12):1813-1820. PubMed ID: 31670874
[TBL] [Abstract][Full Text] [Related]
18. Effects of Intensive Blood Pressure Lowering on Kidney Tubule Injury in CKD: A Longitudinal Subgroup Analysis in SPRINT.
Malhotra R; Craven T; Ambrosius WT; Killeen AA; Haley WE; Cheung AK; Chonchol M; Sarnak M; Parikh CR; Shlipak MG; Ix JH;
Am J Kidney Dis; 2019 Jan; 73(1):21-30. PubMed ID: 30291012
[TBL] [Abstract][Full Text] [Related]
19. Role of Diuretics in Cardiovascular Events and Mortality in Systolic Blood Pressure Intervention Trial: A Post Hoc Analysis.
Bansal S; Boucher R; Shen J; Wei G; Chertow GM; Whelton PK; Cushman WC; Cheung AK; Beddhu S;
Clin J Am Soc Nephrol; 2024 May; 19(5):620-627. PubMed ID: 38262377
[TBL] [Abstract][Full Text] [Related]
20. Estimated glomerular filtration rate and the risk-benefit profile of intensive blood pressure control amongst nondiabetic patients: a post hoc analysis of a randomized clinical trial.
Obi Y; Kalantar-Zadeh K; Shintani A; Kovesdy CP; Hamano T
J Intern Med; 2018 Mar; 283(3):314-327. PubMed ID: 29044764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
